Latest filing published 05 Oct 2026 for Jazz Pharmaceuticals plc, €1.2M. Read the official filing
Bruce C. Cozadd, listed as chief executive, appears in our data through filings on Jazz Pharmaceuticals plc shares, published by SEC (Form 4). In total, 59 filings cover trades dated from 12 January 2016 to 1 October 2026.
On the market, this insider has only sold: 32 sales, €12.0M in total. No amount is published for 2 filings, which the totals therefore leave out. The rest of the record consists of 11 share grants and 15 option exercises. So far in 2026, the count stands at no purchases and 8 sales.
The latest filing, published on 5 October 2026, reports an open-market sale of €1.2M in Jazz Pharmaceuticals plc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 59 declarations